[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 35 of about 35
1. Adedoyin OT, Johnson AW, Ojuawo AI, Afolayan EA, Adeniji KA: Malignant melanoma in a black child: predisposing precursors and management. J Natl Med Assoc; 2004 Oct;96(10):1368-73
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in a black child: predisposing precursors and management.
  • Malignant melanoma (MM) remains a pediatric rarity world-wide, but perhaps more so in black Africans.
  • Primary neoplastic transformation and metastatic spread were suggested by the appearance of multiple swellings over the "garment" precursor nevus at the posterior trunk, multiple ipsilateral axillary nodal enlargement, and fresh occipital swellings postadmission.
  • Chemotherapy was initiated but was truncated shortly after by parent-pressured discharge.
  • Despite the rarity of MM in a tropical African setting where management options are few, the current case underscores the need for a high clinical index of diagnostic suspicion, an early pursuit of investigative confirmation, and prophylactic excision in children with the predisposing skin lesions, like congenital giant hairy nevus.
  • [MeSH-major] African Continental Ancestry Group / genetics. Dysplastic Nevus Syndrome / complications. Melanoma / etiology. Skin Neoplasms / complications
  • [MeSH-minor] Causality. Child, Preschool. Female. Humans. Lymph Nodes / pathology. Nigeria. Risk Factors. Skin Pigmentation / genetics

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cutis. 1999 May;63(5):293-8 [10349545.001]
  • [Cites] J Am Med Assoc. 1951 Nov 3;147(10):941-3 [14873600.001]
  • [Cites] Arch Dermatol. 1965 Feb;91:100-19 [14237589.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] Br J Dermatol. 1968 Jun;80(6):362-6 [5701724.001]
  • [Cites] Pediatrics. 1975 Feb;55(2):191-204 [1090894.001]
  • [Cites] Arch Dermatol. 1975 Dec;111(12):1658 [1200672.001]
  • [Cites] Br J Plast Surg. 1977 Oct;30(4):321-3 [588799.001]
  • [Cites] JAMA. 1978 Feb 20;239(8):744-6 [621895.001]
  • [Cites] JAMA. 1979 Dec 21;242(25):2795-9 [501893.001]
  • [Cites] J Am Acad Dermatol. 1979 Aug;1(2):123-30 [391836.001]
  • [Cites] J Am Acad Dermatol. 1979 Dec;1(6):503-5 [528699.001]
  • [Cites] Br J Dermatol. 1981 Mar;104(3):307-15 [7213564.001]
  • [Cites] Plast Reconstr Surg. 1981 Jun;67(6):782-90 [7243980.001]
  • [Cites] J Clin Oncol. 1984 Nov;2(11):1229-34 [6491702.001]
  • [Cites] Cancer. 1987 Oct 15;60(8):1720-3 [3651999.001]
  • [Cites] Important Adv Oncol. 1988;:217-57 [3042605.001]
  • [Cites] Cancer. 1989 Jan 1;63(1):199-203 [2910418.001]
  • [Cites] J Am Acad Dermatol. 1990 Feb;22(2 Pt 1):159-76 [2179292.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):438-41 [2009058.001]
  • [Cites] J Clin Oncol. 1991 Aug;9(8):1403-8 [2072144.001]
  • [Cites] Cancer Res. 1991 Sep 15;51(18 Suppl):5074s-5079s [1884383.001]
  • [Cites] Cancer. 1995 Jan 1;75(1):43-6 [7804976.001]
  • [Cites] N Engl J Med. 1995 Mar 9;332(10):656-62 [7845431.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):334-6 [7638982.001]
  • [Cites] Cancer. 1995 Nov 15;76(10):1833-45 [8625056.001]
  • [Cites] Oncology (Williston Park). 1995 Nov;9(11):1149-58; discussion 1163-4, 1167-8 [8703684.001]
  • [Cites] Ann Surg. 1996 Sep;224(3):255-63; discussion 263-6 [8813254.001]
  • [Cites] Ann Surg. 1997 Jan;225(1):1-14 [8998115.001]
  • [Cites] Melanoma Res. 1997 Feb;7(1):63-8 [9067967.001]
  • [Cites] Curr Opin Pediatr. 1998 Aug;10(4):398-404 [9757365.001]
  • [Cites] J Dermatol Surg Oncol. 1978 Feb;4(2):153-8 [624799.001]
  • [Cites] Arch Dermatol. 1978 May;114(5):732-8 [646394.001]
  • (PMID = 15540891.001).
  • [ISSN] 1943-4693
  • [Journal-full-title] Journal of the National Medical Association
  • [ISO-abbreviation] J Natl Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Other-IDs] NLM/ PMC2568537
  •  go-up   go-down


2. Hutchins LF, Moon J, Clark JI, Thompson JA, Lange MK, Flaherty LE, Sondak VK: Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026. Cancer; 2007 Nov 15;110(10):2269-75
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of interferon alpha-2B and thalidomide in patients with disseminated malignant melanoma, phase 2, SWOG 0026.
  • BACKGROUND: Southwest Oncology Group protocol 0026 evaluated interferon alpha-2b plus thalidomide in patients with disseminated melanoma.
  • METHODS: Twenty-six patients with Stage IV melanoma, measurable or nonmeasurable disease, performance status of 0-2, and adequate renal and hepatic functions were registered.
  • One prior systemic therapy for Stage IV disease was required.
  • RESULTS: After 2 sudden deaths and 1 grade 4 treatment-related pulmonary embolism, this study was temporarily closed.
  • The relationship of these events to the treatment was worrisome but not definitive.
  • Grade 3 treatment-related adverse events occurred in 14 of 26 patients.
  • No treatment responses were seen in the 22 evaluable patients.
  • CONCLUSIONS: This regimen demonstrated a lack of response and was associated with multiple severe toxicities.
  • [MeSH-major] Interferon-alpha / therapeutic use. Melanoma / drug therapy. Skin Neoplasms / drug therapy. Thalidomide / therapeutic use

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 American Cancer Society.
  • (PMID = 17932881.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA12644; United States / NCI NIH HHS / CA / CA20319; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA35090; United States / NCI NIH HHS / CA / CA35178; United States / NCI NIH HHS / CA / CA35261; United States / NCI NIH HHS / CA / CA37981; United States / NCI NIH HHS / CA / CA38926; United States / NCI NIH HHS / CA / CA45560; United States / NCI NIH HHS / CA / CA45808; United States / NCI NIH HHS / CA / CA46368; United States / NCI NIH HHS / CA / CA58658; United States / NCI NIH HHS / CA / CA58861; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA76447
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 4Z8R6ORS6L / Thalidomide; 99210-65-8 / interferon alfa-2b
  •  go-up   go-down


3. Coleman A, Augustine CK, Beasley G, Sanders G, Tyler D: Optimizing regional infusion treatment strategies for melanoma of the extremities. Expert Rev Anticancer Ther; 2009 Nov;9(11):1599-609
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimizing regional infusion treatment strategies for melanoma of the extremities.
  • The incidence of malignant melanoma is increasing faster than any other cancer.
  • In cases of recurrent melanoma confined to the extremities, hyperthermic isolated limb perfusion and isolated limb infusion provide a way to isolate the extremity and deliver a dose of chemotherapy several orders of magnitude higher than would be tolerated systemically.
  • Currently, new chemotherapy agents and small-molecule inhibitors are being investigated as a means of overcoming chemoresistance and improving response rates.
  • In patients with advanced cutaneous disease confined to the extremities, evaluation of these new therapies can be very informative, as tissue acquisition at multiple treatment time points is easy owing to the superficial and multifocal nature of the disease.
  • Through studying the biomolecular and genetic alterations in tumor tissue in response to these new therapies, genetically customized treatment regimens in which tumor resistance and sensitivity is predicted and treatment strategy is optimized before treatment begins may soon be available.
  • Progress in regional therapy will prove not only beneficial for patients with disease confined to an extremity, but may also provide insight into developing novel treatment strategies for patients with systemic disease for whom current disease management options are poor.

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2009 Jan 15;15(2):502-10 [19147755.001]
  • [Cites] Ann Surg Oncol. 2008 Nov;15(11):3003-13 [18509706.001]
  • [Cites] Ann Surg Oncol. 2009 May;16(5):1193-201 [19224288.001]
  • [Cites] Cancer. 2009 May 1;115(9):1932-40 [19288571.001]
  • [Cites] J Am Coll Surg. 2009 May;208(5):706-15; discussion 715-7 [19476821.001]
  • [Cites] Cancer. 2009 Oct 15;115(20):4766-74 [19637344.001]
  • [Cites] Surg Gynecol Obstet. 1969 Aug;129(2):305-8 [5815841.001]
  • [Cites] Can J Surg. 2001 Jun;44(3):189-92 [11407828.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • [Cites] Ann Surg Oncol. 2002 Mar;9(2):127-36 [11888868.001]
  • [Cites] Oncogene. 2002 Mar 27;21(13):2000-8 [11960372.001]
  • [Cites] Br J Dermatol. 2002 Apr;146 Suppl 61:1-6 [11966724.001]
  • [Cites] Nature. 2002 Jun 27;417(6892):949-54 [12068308.001]
  • [Cites] Oncogene. 2002 Oct 10;21(46):7001-10 [12370822.001]
  • [Cites] Am J Surg. 2003 Nov;186(5):460-7 [14599607.001]
  • [Cites] Surgery. 2004 Aug;136(2):210-8 [15300182.001]
  • [Cites] J Am Coll Surg. 2004 Sep;199(3):419-27 [15325612.001]
  • [Cites] Cancer. 1967 Sep;20(9):1351-81 [4292219.001]
  • [Cites] Cancer Res. 1981 Apr;41(4):1525-34 [6163526.001]
  • [Cites] Biochem Pharmacol. 1982 Jan 1;31(1):121-4 [7059344.001]
  • [Cites] Biochem Pharmacol. 1983 Jan 1;32(1):165-7 [6830612.001]
  • [Cites] Cancer Res. 1984 Nov;44(11):5427-31 [6488194.001]
  • [Cites] Cancer. 1985 Jun 1;55(11):2638-44 [3995475.001]
  • [Cites] Am J Surg. 1985 Jul;150(1):32-5 [4014570.001]
  • [Cites] Anticancer Res. 1987 May-Jun;7(3 Pt B):441-2 [3631900.001]
  • [Cites] Cancer Res. 1987 Nov 15;47(22):6022-7 [3664506.001]
  • [Cites] Cancer. 1989 Jun 15;63(12):2551-61 [2720604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Feb;20(2):287-9 [1991690.001]
  • [Cites] J Clin Oncol. 1992 Jan;10(1):52-60 [1727926.001]
  • [Cites] Int J Hyperthermia. 1993 Mar-Apr;9(2):205-17 [8468505.001]
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Eur J Cancer. 1993;29A(3):325-8 [8398326.001]
  • [Cites] J Am Coll Surg. 1994 Jun;178(6):564-72 [8193749.001]
  • [Cites] World J Surg. 1995 May-Jun;19(3):363-8 [7638989.001]
  • [Cites] Crit Rev Biochem Mol Biol. 1995;30(6):445-600 [8770536.001]
  • [Cites] Arch Surg. 1997 Aug;132(8):903-7 [9267277.001]
  • [Cites] Cancer Res. 1997 Oct 15;57(20):4593-9 [9377574.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):224-31 [9548605.001]
  • [Cites] Semin Surg Oncol. 1998 Apr-May;14(3):238-47 [9548607.001]
  • [Cites] J Clin Oncol. 1998 Sep;16(9):2906-12 [9738557.001]
  • [Cites] J Am Coll Surg. 1999 May;188(5):522-30 [10235581.001]
  • [Cites] Ann Surg. 1958 Oct;148(4):616-32 [13583933.001]
  • [Cites] Ann Surg. 1959 May;149(5):627-40 [13637680.001]
  • [Cites] Eur J Surg Oncol. 2004 Dec;30(10):1107-12 [15522559.001]
  • [Cites] Arch Surg. 2004 Nov;139(11):1237-42 [15545572.001]
  • [Cites] Am J Surg. 2004 Nov;188(5):532-7 [15546565.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):587-96 [16021533.001]
  • [Cites] Arch Surg. 2005 Nov;140(11):1115-20 [16301451.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):289-97 [16397054.001]
  • [Cites] Mol Cancer Ther. 2006 Mar;5(3):732-8 [16546988.001]
  • [Cites] N Engl J Med. 2006 Jul 6;355(1):51-65 [16822996.001]
  • [Cites] J Clin Oncol. 2006 Sep 1;24(25):4196-201 [16943537.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1123-9 [16791448.001]
  • [Cites] Ann Surg Oncol. 2006 Aug;13(8):1105-12 [16865591.001]
  • [Cites] Ann Surg. 2007 Apr;245(4):591-6 [17414608.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1492-500 [17483437.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3942-50 [17606728.001]
  • [Cites] Int J Hyperthermia. 2008 May;24(3):185-92 [18392997.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3777-84 [18483261.001]
  • [Cites] Ann Surg Oncol. 2008 Aug;15(8):2195-205 [18528730.001]
  • [Cites] Ann Surg Oncol. 2009 Apr;16(4):953-61 [19184236.001]
  • (PMID = 19895244.001).
  • [ISSN] 1744-8328
  • [Journal-full-title] Expert review of anticancer therapy
  • [ISO-abbreviation] Expert Rev Anticancer Ther
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA074241-04; United States / NCRR NIH HHS / RR / TL1 RR024126; United States / NCI NIH HHS / CA / K08 CA074241-04; United States / NCRR NIH HHS / RR / TL1RR024126
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 65
  • [Other-IDs] NLM/ NIHMS169083; NLM/ PMC2819027
  •  go-up   go-down


Advertisement
4. Health Quality Ontario: Extracorporeal photophoresis: an evidence-based analysis. Ont Health Technol Assess Ser; 2006;6(6):1-82

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To assess the effectiveness, safety and cost-effectiveness of extracorporeal photophoresis (ECP) for the treatment of refractory erythrodermic cutaneous T cell lymphoma (CTCL) and refractory chronic graft versus host disease (cGvHD).
  • BACKGROUND: CUTANEOUS T CELL LYMPHOMA: Cutaneous T cell lymphoma (CTCL) is a general name for a group of skin affecting disorders caused by malignant white blood cells (T lymphocytes).
  • The relative frequency and disease-specific 5-year survival of 1,905 primary cutaneous lymphomas classified according to the World Health Organization-European Organization for Research and Treatment of Cancer (WHO-EORTC) classification (Appendix 1).
  • Cutaneous T cell lymphoma has an annual incidence of approximately 0.4 per 100,000 and it mainly occurs in the 5(th) to 6(th) decade of life, with a male/female ratio of 2:1.
  • Mycosis fungoides is an indolent lymphoma with patients often having several years of eczematous or dermatitic skin lesions before the diagnosis is finally established.
  • Early in the disease biopsies are often difficult to interpret and the diagnosis may only become apparent by observing the patient over time.
  • Most patients will live normal lives and experience skin symptoms without serious complications.
  • A particular syndrome in these patients involves erythroderma (intense and usually widespread reddening of the skin from dilation of blood vessels, often preceding or associated with exfoliation), and circulating tumour cells.
  • CHRONIC GRAFT VERSUS HOST DISEASE: Allogeneic hematopoietic cell transplantation (HCT) is a treatment used for a variety of malignant and nonmalignant disease of the bone marrow and immune system.
  • The procedure is often associated with serious immunological complications, particularly graft versus host disease (GvHD).
  • Of the patients with extensive disease, approximately 60% will respond to treatment and eventually be able to discontinue immunosuppressive therapy.
  • The remaining patients will develop opportunistic infection, or require prolonged treatment with immunosuppressive agents.
  • The extent of involvement varies significantly from mild involvement limited to a few patches of skin to severe involvement of numerous organ systems and profound immunodeficiency.
  • The most commonly involved tissues are the skin, liver, mouth, and eyes.
  • Patients with limited disease have localized skin involvement, evidence of liver dysfunction, or both, whereas those with more involvement of the skin or involvement of other organs have extensive disease.
  • TREATMENT:   CUTANEOUS T CELL LYMPHOMA: The optimal management of MF is undetermined because of its low prevalence, and its highly variable natural history, with frequent spontaneous remissions and exacerbations and often prolonged survival.
  • Nonaggressive approaches to therapy are usually warranted with treatment aimed at improving symptoms and physical appearance while limiting toxicity.
  • Given that multiple skin sites are usually involved, the initial treatment choices are usually topical or intralesional corticosteroids or phototherapy using psoralen (a compound found in plants which make the skin temporarily sensitive to ultraviolet A) (PUVA).
  • Repeated courses are usually required which may lead to an increased risk of both melanoma and nonmelanoma skin cancer.
  • "Second line" therapy for early stage disease is often topical chemotherapy, radiotherapy or total skin electron beam radiation (TSEB).
  • Treatment of advanced stage (IIB-IV) MF usually consists of topical or systemic therapy in refractory or rapidly progressive SS.
  • Bone marrow transplantation and peripheral blood stem cell transplantation have been used to treat many malignant hematologic disorders (e.g., leukemias) that are refractory to conventional treatment.
  • Reports on the use of these procedures for the treatment of CTCL are limited and mostly consist of case reports or small case series.
  • CHRONIC GRAFT VERSUS HOST DISEASE: Patients who develop cGvHD require reinstitution of immunosuppressive medication (if already discontinued) or an increase in dosage and possibly addition of other agents.
  • The current literature regarding cGvHD therapy is less than optimal and many recommendations about therapy are based on common practices that await definitive testing.
  • Numerous salvage therapies have been considered in patients with refractory cGvHD, including ECP.
  • Due to uncertainty around salvage therapies, Bhushan and Collins suggested that ideally, patients with refractory cGvHD should be entered into clinical trials.
  • Two Ontario expert consultants jointly estimated that there may be approximately 30 new erythrodermic treatment resistant CTCL patients and 30 new treatment resistant cGvHD patients per year who are unresponsive to other forms of therapy and may be candidates for ECP.
  • Extracorporeal photopheresis is a procedure that was initially developed as a treatment for CTCL, particularly SS.
  • The lymphocyte layer is treated with methoxsalen (a drug that sensitizes the lymphocytes to light) and exposed to UVA, following which the lymphocytes are returned to the patient.
  • Photosensitization is achieved by administering methoxsalen to the patient orally 2 hours before the procedure, or by injecting methoxsalen directly ino the leucocyte rich fraction.
  • The latter approach avoids potential side effects such as nausea, and provides a more consistent drug level within the machine.
  • In general, from the time the intravenous line is inserted until the white blood cells are returned to the patient takes approximately 2.5-3.5 hours.
  • For CTCL, the treatment schedule is generally 2 consecutive days every 4 weeks for a median of 6 months.
  • For cGvHD, an expert in the field estimated that the treatment schedule would be 3 times a week for the 1(st) month, then 2 consecutive days every 2 weeks after that (i.e., 4 treatments a month) for a median of 6 to 9 months.
  • REGULATORY STATUS: The UVAR XTS Photopheresis System is licensed by Health Canada as a Class 3 medical device (license # 7703) for the "palliative treatment of skin manifestations of CTCL."
  • It is not licensed for the treatment of cGvHD.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Acad Dermatol. 1998 Feb;38(2 Pt 1):207-20 [9486676.001]
  • [Cites] J Am Acad Dermatol. 1996 Oct;35(4):573-9 [8859287.001]
  • [Cites] J Cutan Med Surg. 2003 Jul-Aug;7(4 Suppl):13-7 [12958702.001]
  • [Cites] Cancer. 1988 Oct 15;62(8):1658-61 [3167782.001]
  • [Cites] Blood. 2003 Aug 15;102(4):1217-23 [12714516.001]
  • [Cites] J Am Acad Dermatol. 1992 Sep;27(3):427-33 [1401279.001]
  • [Cites] N Engl J Med. 1987 Feb 5;316(6):297-303 [3543674.001]
  • [Cites] Arch Dermatol. 2002 Oct;138(10):1347-50 [12374541.001]
  • [Cites] J Am Acad Dermatol. 1992 Nov;27(5 Pt 1):729-36 [1430395.001]
  • [Cites] Cancer Treat Rep. 1979 Apr;63(4):701-7 [376140.001]
  • [Cites] Blood. 2005 May 15;105(10):3768-85 [15692063.001]
  • [Cites] J Clin Oncol. 2003 Apr 1;21(7):1404-11 [12663734.001]
  • [Cites] Ann Intern Med. 1988 Sep 1;109(5):372-82 [3408055.001]
  • [Cites] Arch Dermatol. 1998 Aug;134(8):1001-5 [9722731.001]
  • [Cites] J Am Acad Dermatol. 2001 Feb;44(2):253-60 [11174383.001]
  • [Cites] J Am Acad Dermatol. 2000 Aug;43(2 Pt 1):263-71 [10906649.001]
  • [Cites] Br J Dermatol. 2000 Jan;142(1):16-21 [10651689.001]
  • [Cites] Bone Marrow Transplant. 2005 Jun;35(12):1187-93 [15852025.001]
  • [Cites] BMJ. 2004 Jun 19;328(7454):1490 [15205295.001]
  • [Cites] Cancer. 2001 Oct 1;92(7):1745-52 [11745245.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):935-45 [8959953.001]
  • [Cites] Yale J Biol Med. 1989 Nov-Dec;62(6):629-38 [2534648.001]
  • [Cites] J Cutan Pathol. 1997 May;24(5):286-91 [9194581.001]
  • [Cites] Br J Dermatol. 2006 Jan;154(1):7-20 [16403088.001]
  • [Cites] Cancer. 1981 Jun 1;47(11):2671-7 [7260860.001]
  • [Cites] Ann Intern Med. 1994 Oct 15;121(8):592-602 [8085692.001]
  • [Cites] Bone Marrow Transplant. 2003 Mar;31(6):459-65 [12665841.001]
  • [Cites] Lancet. 1997 Jul 5;350(9070):32-3 [9217723.001]
  • [Cites] Int J Artif Organs. 2000 Jan;23(1):55-62 [12118838.001]
  • [Cites] Blood. 2001 Sep 1;98(5):1298-301 [11520774.001]
  • [Cites] JAMA. 2003 Nov 19;290(19):2599-603 [14625337.001]
  • [Cites] Blood. 1987 Mar;69(3):841-9 [3493044.001]
  • [Cites] Br J Haematol. 2005 Jul;130(2):271-5 [16029456.001]
  • [Cites] Arch Dermatol. 2002 Aug;138(8):1054-60 [12164743.001]
  • [Cites] J Am Acad Dermatol. 1993 Apr;28(4):580-4 [8463458.001]
  • [Cites] Lancet. 1997 Sep 20;350(9081):886 [9310623.001]
  • [Cites] N Engl J Med. 1989 Dec 28;321(26):1784-90 [2594037.001]
  • [Cites] Br J Dermatol. 2004 Feb;150(2):327-36 [14996105.001]
  • [Cites] J Am Acad Dermatol. 2000 Jul;43(1 Pt 1):54-60 [10863224.001]
  • [Cites] Lancet. 2001 Mar 17;357(9259):820-1 [11265946.001]
  • [Cites] Blood. 2006 Apr 15;107(8):3074-80 [16368882.001]
  • [Cites] Br J Haematol. 2003 Jul;122(1):118-27 [12823353.001]
  • [Cites] Clin Exp Dermatol. 2004 May;29(3):231-6 [15115499.001]
  • [Cites] J Am Acad Dermatol. 1996 Dec;35(6):946-57 [8959954.001]
  • [Cites] Ann N Y Acad Sci. 1991 Dec 30;636:171-7 [1793207.001]
  • [Cites] J Am Acad Dermatol. 1997 Mar;36(3 Pt 1):460-6 [9091480.001]
  • [Cites] Br J Dermatol. 2005 Jul;153(1):1-5 [16033336.001]
  • (PMID = 23074497.001).
  • [Journal-full-title] Ontario health technology assessment series
  • [ISO-abbreviation] Ont Health Technol Assess Ser
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Canada
  • [Other-IDs] NLM/ PMC3379535
  •  go-up   go-down


5. Beloueche-Babari M, Arunan V, Jackson LE, Perusinghe N, Sharp SY, Workman P, Leach MO: Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition. Oncotarget; 2010 Jul;1(3):185-97
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Modulation of melanoma cell phospholipid metabolism in response to heat shock protein 90 inhibition.
  • Molecular chaperone heat shock protein 90 (Hsp90) inhibitors are promising targeted cancer therapeutic drugs, with the advantage that they deplete multiple oncogenic client proteins and modulate all the classical hallmarks of cancer.
  • They are now in clinical trial and show potential for activity in melanoma and other malignancies.
  • Here we explore the metabolic response to Hsp90 inhibition in human melanoma cells using magnetic resonance spectroscopy.
  • We show that, concomitant with growth inhibition and re-differentiation, Hsp90 inhibition in human melanoma cells is associated with increased glycerophosphocholine content.
  • This was seen with both the clinical geldanamycin-based Hsp90 drug 17-AAG and the structurally dissimilar Hsp90 inhibitor CCT018159.
  • The effect was noted in both BRAF mutant SKMEL28 and BRAF wildtype CHL-1 melanoma cells.
  • Our findings provide a basis for using metabolic changes as non-invasive indicators of Hsp90 inhibition and potentially as biomarkers of anticancer activity with Hsp90 drugs in malignant melanoma and possibly in other cancers.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Benzoquinones / pharmacology. HSP90 Heat-Shock Proteins / antagonists & inhibitors. Lactams, Macrocyclic / pharmacology. Melanoma / drug therapy. Melanoma / metabolism. Skin Neoplasms / drug therapy. Skin Neoplasms / metabolism
  • [MeSH-minor] Biomarkers, Pharmacological. Glycerylphosphorylcholine / metabolism. Heterocyclic Compounds, 2-Ring / chemistry. Heterocyclic Compounds, 2-Ring / pharmacology. Humans. Lipid Metabolism / drug effects. Magnetic Resonance Spectroscopy. Mutation / genetics. Naphthalenes / pharmacology. Phospholipase A2 Inhibitors. Proto-Oncogene Proteins B-raf / genetics. Proto-Oncogene Proteins B-raf / metabolism. Pyrazoles / chemistry. Pyrazoles / pharmacology. Pyrones / pharmacology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Neoplasia. 2008 Apr;10(4):303-13 [18392140.001]
  • [Cites] Cell Metab. 2008 Jan;7(1):11-20 [18177721.001]
  • [Cites] Mol Cancer Ther. 2008 Apr;7(4):737-9 [18375819.001]
  • [Cites] Cancer Cell. 2008 Sep 9;14(3):250-62 [18772114.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):370-4 [18644253.001]
  • [Cites] Arthritis Rheum. 2008 Dec;58(12):3765-75 [19035474.001]
  • [Cites] Clin Cancer Res. 2008 Dec 15;14(24):8302-7 [19088048.001]
  • [Cites] FEBS Lett. 2009 May 19;583(10):1611-8 [19393651.001]
  • [Cites] Carcinogenesis. 2009 Aug;30(8):1269-80 [19321800.001]
  • [Cites] Magn Reson Med. 2009 Nov;62(5):1112-9 [19780165.001]
  • [Cites] Br J Cancer. 2010 Jan 5;102(1):1-7 [19935796.001]
  • [Cites] Nat Med. 1999 Nov;5(11):1323-7 [10546002.001]
  • [Cites] Cancer Res. 2001 Apr 1;61(7):2945-52 [11306472.001]
  • [Cites] Cancer Res. 2001 May 15;61(10):4003-9 [11358818.001]
  • [Cites] Expert Opin Biol Ther. 2002 Jan;2(1):3-24 [11772336.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1890-7 [11912170.001]
  • [Cites] Br J Cancer. 2002 Mar 18;86(6):963-70 [11953830.001]
  • [Cites] Br J Cancer. 2002 Sep 23;87(7):783-9 [12232764.001]
  • [Cites] J Natl Cancer Inst. 2003 Nov 5;95(21):1624-33 [14600095.001]
  • [Cites] Cancer Res. 2004 Jun 15;64(12):4270-6 [15205341.001]
  • [Cites] Mol Cancer Ther. 2004 Aug;3(8):1021-30 [15299085.001]
  • [Cites] Melanoma Res. 1991 Nov-Dec;1(4):223-30 [1823630.001]
  • [Cites] NMR Biomed. 1992 Sep-Oct;5(5):303-24 [1333263.001]
  • [Cites] NMR Biomed. 1993 Nov-Dec;6(6):345-65 [8148230.001]
  • [Cites] J Biol Chem. 1994 Dec 16;269(50):31693-700 [7989342.001]
  • [Cites] J Biol Chem. 1996 Aug 23;271(34):20219-22 [8702749.001]
  • [Cites] J Biol Chem. 1996 Dec 13;271(50):31937-41 [8943239.001]
  • [Cites] NMR Biomed. 1998 Nov;11(7):314-40 [9859939.001]
  • [Cites] Cancer Res. 2010 Mar 1;70(5):2126-35 [20179205.001]
  • [Cites] Nat Rev Cancer. 2010 Apr;10(4):267-77 [20300106.001]
  • [Cites] Oncol Rep. 2010 Jun;23(6):1709-14 [20428829.001]
  • [Cites] Cancer Res. 2008 Apr 15;68(8):2850-60 [18413753.001]
  • [Cites] Cancer Res. 1999 Jan 1;59(1):80-4 [9892190.001]
  • [Cites] J Biol Chem. 1999 Apr 2;274(14):9400-8 [10092620.001]
  • [Cites] Biochim Biophys Acta. 2005 May 1;1734(1):1-12 [15866478.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4152-61 [15961763.001]
  • [Cites] Bioorg Med Chem Lett. 2005 Jul 15;15(14):3338-43 [15955698.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9369-76 [16230400.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10686-91 [16322212.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jan 3;103(1):57-62 [16371460.001]
  • [Cites] Mol Cancer Ther. 2006 Jan;5(1):187-96 [16432178.001]
  • [Cites] Handb Exp Pharmacol. 2006;(172):331-58 [16610366.001]
  • [Cites] Biochim Biophys Acta. 2006 Nov;1761(11):1246-59 [16973413.001]
  • [Cites] Endocr Relat Cancer. 2006 Dec;13 Suppl 1:S125-35 [17259553.001]
  • [Cites] Cancer Res. 2007 Mar 1;67(5):2206-16 [17332351.001]
  • [Cites] Mol Cancer Ther. 2007 Apr;6(4):1198-211 [17431102.001]
  • [CommentIn] Oncotarget. 2010 Jul;1(3):163-6 [21301046.001]
  • (PMID = 21037799.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / / C1060/6916; United Kingdom / Medical Research Council / / ; United Kingdom / Cancer Research UK / / A10334; United Kingdom / Department of Health / / ; United Kingdom / Cancer Research UK / / C1060/A10334; United Kingdom / Cancer Research UK / / C309/A8274; United Kingdom / Cancer Research UK / / A8274; United Kingdom / Cancer Research UK / / A6916
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / Biomarkers, Pharmacological; 0 / CCT018159; 0 / HSP90 Heat-Shock Proteins; 0 / Heterocyclic Compounds, 2-Ring; 0 / Lactams, Macrocyclic; 0 / Naphthalenes; 0 / Phospholipase A2 Inhibitors; 0 / Pyrazoles; 0 / Pyrones; 4GY0AVT3L4 / tanespimycin; 60M22SGW66 / Glycerylphosphorylcholine; 88070-98-8 / 6-(bromomethylene)tetrahydro-3-(1-naphthaleneyl)-2H-pyran-2-one; EC 2.7.11.1 / BRAF protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins B-raf
  • [Keywords] NOTNLM ; Hsp90 / MRS / melanoma / metabolism / phospholipid
  •  go-up   go-down


6. Oosting SF, Peters FT, Hospers GA, Mulder NH: A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report. J Med Case Rep; 2010;4:10

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A patient with metastatic melanoma presenting with gastrointestinal perforation after dacarbazine infusion: a case report.
  • INTRODUCTION: We report a rare case of gastrointestinal perforation following dacarbazine infusion for metastatic melanoma.
  • The condition is attributed to a responding malignant melanoma in the gastrointestinal tract.
  • A computed tomography scan showed massive ascites, lymphadenopathy and liver lesions suspect for metastases.
  • An upper gastrointestinal endoscopy was performed and revealed multiple dark lesions of 5 mm to 10 mm in his stomach and duodenum.When his skin was re-examined, an irregular pigmented lesion over the left clavicle measuring 15 mm x 8 mm with partial depigmentation was found.
  • Histological examination of a duodenal lesion was consistent with a diagnosis of metastatic melanoma.
  • The patient was started on systemic treatment with dacarbazine 800 mg/m2 every three weeks and he was discharged one day after the first dose.
  • A laparotomy was discussed with the patient and his family but he decided to go home with symptomatic treatment.
  • CONCLUSION: Melanoma can originate in, as well as metastasize to, the gastrointestinal tract.
  • Gastrointestinal perforations due to responding tumors are a well-known complication of systemic treatment of gastrointestinal lymphomas.
  • However, as the response rate of metastatic melanoma to dacarbazine is only 10% to 20%, and responses are usually only partial, perforation due to treatment response in metastatic melanoma is rare.Medical oncologists should be aware of the risk of bowel perforation after starting cytotoxic chemotherapy on patients with gastrointestinal metastases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1978 Jun;135(6):807-10 [665907.001]
  • [Cites] Cancer. 1988 May 15;61(10):2134-5 [3359409.001]
  • [Cites] J Pediatr Surg. 1999 Jul;34(7):1169-74 [10442615.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] Cancer Treat Rev. 2008 Apr;34(2):145-56 [18077098.001]
  • [Cites] Cochrane Database Syst Rev. 2000;(2):CD001215 [10796759.001]
  • [Cites] Arch Surg. 1964 Jun;88:969-73 [14132002.001]
  • [Cites] Mayo Clin Proc. 2006 Apr;81(4):511-6 [16610571.001]
  • [Cites] J Pediatr Surg. 2007 Mar;42(3):E1-3 [17336175.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • (PMID = 20180962.001).
  • [ISSN] 1752-1947
  • [Journal-full-title] Journal of medical case reports
  • [ISO-abbreviation] J Med Case Rep
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2829594
  •  go-up   go-down


7. Zheng M, Bocangel D, Ramesh R, Ekmekcioglu S, Poindexter N, Grimm EA, Chada S: Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells. Mol Cancer Ther; 2008 Dec;7(12):3842-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Interleukin-24 overcomes temozolomide resistance and enhances cell death by down-regulation of O6-methylguanine-DNA methyltransferase in human melanoma cells.
  • Melanoma is the most malignant of skin cancers, highly resistant to chemotherapy and radiotherapy.
  • Temozolomide, a promising new derivative of dacarbazine, is currently being tested for treatment of metastatic melanoma.
  • Interleukin-24 (IL-24; mda-7) is a tumor suppressor cytokine that selectively inhibits tumor cell growth by inducing apoptosis and cell cycle arrest in melanoma cell lines and solid tumors.
  • This tumor-selective activity has been observed in multiple preclinical animal models and in clinical trials.
  • In this study, we analyzed the ability of Ad-IL-24 and its protein product, IL-24, to overcome temozolomide resistance in human melanoma cells.
  • We have shown that Ad-IL-24 via exogenous IL-24 protein induces combinatorial synergy of temozolomide-induced cell killing in temozolomide-resistant melanoma cells by inhibition of MGMT.
  • Neutralizing antibodies against IL-24 or its receptors significantly blocked the apoptotic activity of IL-24 + MGMT treatment.
  • However, MGMT blockade in combination with IL-24 + temozolomide resulted in loss of combinatorial synergy, indicating that MGMT expression is required for the reversal of temozolomide resistance in melanoma cells.

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pharmacol Exp Ther. 2003 Feb;304(2):661-8 [12538819.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7573-9 [16140920.001]
  • [Cites] Oncogene. 2003 Nov 27;22(54):8758-73 [14647471.001]
  • [Cites] J Neurochem. 2006 Feb;96(3):766-76 [16405512.001]
  • [Cites] Toxicol Appl Pharmacol. 2006 Mar 1;211(2):97-105 [16039682.001]
  • [Cites] Cancer Gene Ther. 2006 May;13(5):490-502 [16282987.001]
  • [Cites] Int J Hematol. 2006 May;83(4):341-7 [16757436.001]
  • [Cites] Int J Oncol. 2006 Oct;29(4):785-97 [16964376.001]
  • [Cites] Cancer Immunol Immunother. 2007 Feb;56(2):205-15 [16710719.001]
  • [Cites] Oncogene. 2007 Jan 11;26(2):186-97 [16819506.001]
  • [Cites] Mol Cancer Ther. 2007 May;6(5):1492-500 [17483437.001]
  • [Cites] Mol Cancer. 2007;6:36 [17547775.001]
  • [Cites] Cancer Chemother Pharmacol. 2008 Apr;61(4):653-9 [17564708.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2762-71 [10561351.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Mol Med. 2001 Apr;7(4):271-82 [11471572.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7051-63 [11704829.001]
  • [Cites] J Clin Oncol. 2002 Feb 15;20(4):1069-74 [11844832.001]
  • [Cites] Oncogene. 2002 Jul 4;21(29):4558-66 [12085234.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jul 23;99(15):10054-9 [12114539.001]
  • [Cites] Cytokine Growth Factor Rev. 2003 Feb;14(1):35-51 [12485618.001]
  • [Cites] Int Immunopharmacol. 2004 May;4(5):649-67 [15120650.001]
  • [Cites] Semin Oncol. 2004 Apr;31(2 Suppl 4):33-7 [15124132.001]
  • [Cites] Leuk Res. 1987;11(12):1141-8 [3480403.001]
  • [Cites] Cancer Chemother Pharmacol. 1989;25(3):149-55 [2557170.001]
  • [Cites] Eur J Cancer. 1993;29A(7):940-2 [8499146.001]
  • [Cites] Br J Cancer. 1993 Jun;67(6):1299-302 [8512814.001]
  • [Cites] Br J Cancer. 1994 Mar;69(3):452-6 [8123472.001]
  • [Cites] Genes Dev. 1994 May 15;8(10):1235-46 [7926727.001]
  • [Cites] Mol Cell Biol. 1994 Oct;14(10):6515-21 [7523853.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] Oncogene. 1995 Dec 21;11(12):2477-86 [8545104.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9160-5 [8799171.001]
  • [Cites] J Pharmacol Exp Ther. 1996 Oct;279(1):416-22 [8859021.001]
  • [Cites] Blood. 1997 Mar 1;89(5):1566-73 [9057638.001]
  • [Cites] Cancer Treat Rev. 1997 Jan;23(1):35-61 [9189180.001]
  • [Cites] Cancer Chemother Pharmacol. 1997;40(3):266-72 [9219512.001]
  • [Cites] Mol Pharmacol. 1997 Aug;52(2):249-58 [9271347.001]
  • [Cites] Br J Cancer. 1998 Nov;78(9):1199-202 [9820180.001]
  • [Cites] Mol Ther. 2004 Dec;10(6):1085-95 [15564140.001]
  • [Cites] Mol Ther. 2005 Jan;11(1):149-59 [15585416.001]
  • [Cites] Mol Ther. 2005 Jan;11(1):160-72 [15585417.001]
  • [Cites] Cancer Res. 2005 Apr 15;65(8):3319-27 [15833865.001]
  • [Cites] Mol Ther. 2005 May;11(5):724-33 [15851011.001]
  • [Cites] Cancer Res. 2005 Jul 15;65(14):6394-400 [16024643.001]
  • [Cites] Clin Cancer Res. 2005 Jul 15;11(14):5167-74 [16033832.001]
  • [Cites] J Chemother. 2003 Apr;15(2):173-83 [12797396.001]
  • (PMID = 19056673.001).
  • [ISSN] 1535-7163
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R41 CA088421-01; United States / NCI NIH HHS / CA / R42-CA89778; United States / NCI NIH HHS / CA / R41 CA089778; United States / NCI NIH HHS / CA / CA088421-01; United States / NCI NIH HHS / CA / CA097598; United States / NCI NIH HHS / CA / R42 CA089778-07; United States / NCI NIH HHS / CA / R43 CA097598-01; United States / NCI NIH HHS / CA / R42 CA089778; United States / NCI NIH HHS / CA / CA88421; United States / NCI NIH HHS / CA / CA89778; United States / NCI NIH HHS / CA / P50CA093459; United States / NCI NIH HHS / CA / R41-CA89778; United States / NCI NIH HHS / CA / R41 CA089778-02; United States / NCI NIH HHS / CA / P50 CA093459-01A1; United States / NCI NIH HHS / CA / P50 CA093459; United States / NCI NIH HHS / CA / CA089778-02; United States / NCI NIH HHS / CA / CA097598-01; United States / NCI NIH HHS / CA / CA089778-07
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Interleukins; 0 / Tumor Suppressor Protein p53; 0 / interleukin-24; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; EC 2.1.1.63 / O(6)-Methylguanine-DNA Methyltransferase
  • [Other-IDs] NLM/ NIHMS84623; NLM/ PMC2653264
  •  go-up   go-down


8. Padsis J, Turley R, Tyler D: Pharmacotherapy of regional melanoma therapy. Expert Opin Pharmacother; 2010 Jan;11(1):79-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pharmacotherapy of regional melanoma therapy.
  • IMPORTANCE OF THE FIELD: In-transit melanoma metastases develop within regional dermal and subdermal lymphatics before reaching the regional lymph nodes.
  • The prognosis is poor and comparable to multiple nodal metastases.
  • Isolated limb infusion (ILI) or perfusion (ILP) are effective treatments for unresectable, in-transit melanoma, with response rates reaching 95%.
  • Although ILI and ILP are more effective than systemic therapy, most patients will recur, thus highlighting the need for newer strategies to improve durable response rates.
  • AREAS COVERED IN THIS REVIEW: We review historical and current literature from 1958 to 2009 regarding regional therapy for melanoma, with focus on the ILI and ILP techniques, pharmacokinetics and resistance mechanisms of melphalan.
  • Alternative therapies, adjunct strategies and new targeted therapies aimed at improving response rates and long-term remission are also discussed.
  • WHAT THE READER WILL GAIN: The reader will gain a comprehensive review on regional pharmacotherapy for melanoma, including alternative therapies, adjunct strategies and new targeted therapies.
  • TAKE HOME MESSAGE: Regional chemotherapy is a viable, evolving treatment for patients with in-transit melanoma and a springboard for ongoing research aimed at improving therapies for malignant melanoma.
  • [MeSH-major] Antineoplastic Agents, Alkylating / therapeutic use. Extremities / pathology. Lymphatic Metastasis / pathology. Melanoma / pathology. Melphalan / therapeutic use. Neoplasm Recurrence, Local
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Chemotherapy, Cancer, Regional Perfusion. Combined Modality Therapy. Humans. Hyperthermia, Induced / methods. Infusions, Intra-Arterial. Skin Neoplasms / drug therapy. Soft Tissue Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. MELPHALAN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20001431.001).
  • [ISSN] 1744-7666
  • [Journal-full-title] Expert opinion on pharmacotherapy
  • [ISO-abbreviation] Expert Opin Pharmacother
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


9. Guenova E, Lichte V, Hoetzenecker W, Woelbing F, Moehrle M, Roecken M, Schaller M: Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine. Melanoma Res; 2009 Aug;19(4):271-3
Hazardous Substances Data Bank. AZATHIOPRINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Nodular malignant melanoma and multiple cutaneous neoplasms under immunosuppression with azathioprine.
  • Immunosuppressed patients are at increased risk of skin cancer.
  • A 67-year-old renal transplant recipient developed a nodular malignant melanoma after 30 years of immunosuppression with azathioprine and prednisolone.
  • Renal transplant recipients are at high risk of developing nonmelanocytic skin tumors when on immunosuppressive therapy with cyclosporine A.
  • Less common is the development of skin cancer during immunosuppression with azathioprine.
  • Latest reports show the increased incidence of malignant melanoma in immunosuppressed patients.
  • Our case illustrates the necessity of close dermatological surveillance of allograft recipients, to assure an early recognition of any malignant skin tumor and to reduce the risk of systemic metastatic disease.
  • [MeSH-major] Azathioprine / adverse effects. Immunosuppressive Agents / adverse effects. Kidney Transplantation. Melanoma / etiology. Neoplasms, Multiple Primary / etiology. Skin Neoplasms / etiology
  • [MeSH-minor] Aged. Antineoplastic Agents, Alkylating / therapeutic use. Carcinoma, Basal Cell / etiology. Carcinoma, Basal Cell / pathology. Carcinoma, Squamous Cell / etiology. Carcinoma, Squamous Cell / pathology. Dacarbazine / analogs & derivatives. Dacarbazine / therapeutic use. Drug Therapy, Combination. Early Detection of Cancer. Humans. Lymphatic Metastasis. Male. Splenic Neoplasms / secondary

  • Genetic Alliance. consumer health - Nodular melanoma.
  • MedlinePlus Health Information. consumer health - Kidney Transplantation.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. DACARBAZINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19550360.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; 0 / Immunosuppressive Agents; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; MRK240IY2L / Azathioprine
  •  go-up   go-down


10. Chrissos DN, Stougiannos PN, Mytas DZ, Katsaros AA, Andrikopoulos GK, Kallikazaros IE: Multiple cardiac metastases from a malignant melanoma. Eur J Echocardiogr; 2008 May;9(3):391-2
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multiple cardiac metastases from a malignant melanoma.
  • Metastatic tumors in the pericardium or the heart are more common than primary tumors and their incidence has increased during the last decades due to the prolonged survival of patients with cancer and the increased prevalence of the disease in the general population.
  • He had a history of a malignant skin melanoma surgically removed 4 years ago.
  • The echo study identified multiple metastases in the heart involving the pericardium, the myocardium and the right atrium, where the tumor was mobile creating mechanical tricuspid valve stenosis.
  • Malignant metastasis was confirmed by pericardiocentesis and, although treatment with chemotherapy was promptly initiated, the patient died 4 months later.
  • Despite the difficulty in clinical diagnosis of cardiac melanoma, early detection has important therapeutic and prognostic implications.
  • [MeSH-major] Heart Neoplasms / ultrasonography. Melanoma / ultrasonography. Skin Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17347051.001).
  • [ISSN] 1532-2114
  • [Journal-full-title] European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology
  • [ISO-abbreviation] Eur J Echocardiogr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


11. Tsuji M, Nakai N, Ueda E, Takenaka H, Katoh N, Kishimoto S: Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease. J Dermatol; 2010 May;37(5):484-7
MedlinePlus Health Information. consumer health - Vulvar Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Double cancer of plantar malignant melanoma and vulvar extramammary Paget's disease.
  • The plantar lesion was a 15-mm ulcerated nodule located at the center of a 25-mm atypical pigmentation region; the nodule was clinically suspected to be a malignant melanoma.
  • There was no evidence of metastasis in the computed tomography (CT) and (18)F-fluorodeoxyglucose positron emission tomography scans.
  • Melanoma cells were identified in the sentinel lymph nodes, and left radical lymph node dissection was performed after a course of neoadjuvant chemotherapy.
  • All the lymph nodes that were resected during the second operation tested negative for melanomas, and the plantar lesion was diagnosed as a stage IIIB malignant melanoma (pT4b, Na2, M0).
  • Thereafter, we administrated four courses of chemotherapy, and 8 months after the operation, there was no evidence of recurrence or metastatic lesions.
  • We present a case report of double cancer: a plantar malignant melanoma and vulvar EMPD, and also discuss the possible genetic mutations responsible for these two tumors.
  • [MeSH-major] Foot Diseases / pathology. Melanoma / pathology. Neoplasms, Multiple Primary / pathology. Paget Disease, Extramammary / pathology. Skin Neoplasms / pathology. Vulvar Neoplasms / pathology


12. Bogenrieder T, Weitzel C, Schölmerich J, Landthaler M, Stolz W: Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma? Dermatology; 2002;205(2):174-5
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eruptive multiple lentigo-maligna-like lesions in a patient undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing colorectal carcinoma: a lesson for the pathogenesis of malignant melanoma?
  • Induction of multiple eruptive dermal and atypical melanocytic naevi has frequently been reported in children with malignant haematological diseases and chemotherapy-induced immunosuppression.
  • This is the first report of an adult patient to develop multiple eruptive melanocytic skin lesions while undergoing chemotherapy with an oral 5-fluorouracil prodrug for metastasizing cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / adverse effects. Carcinoma / drug therapy. Carcinoma / secondary. Colorectal Neoplasms / pathology. Deoxycytidine / adverse effects. Deoxycytidine / analogs & derivatives. Drug Eruptions / etiology. Hutchinson's Melanotic Freckle / chemically induced. Prodrugs / adverse effects. Skin Neoplasms / diagnosis
  • [MeSH-minor] Administration, Oral. Capecitabine. Fluorouracil. Humans. Male. Melanoma / physiopathology. Middle Aged. Neoplasms, Second Primary / chemically induced. Neoplasms, Second Primary / pathology. Nevus, Pigmented / chemically induced. Nevus, Pigmented / diagnosis. Nevus, Pigmented / pathology. Skin / pathology

  • Genetic Alliance. consumer health - Lentigo maligna melanoma.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12218237.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Prodrugs; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


13. Hayes AJ, Clark MA, Harries M, Thomas JM: Management of in-transit metastases from cutaneous malignant melanoma. Br J Surg; 2004 Jun;91(6):673-82
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of in-transit metastases from cutaneous malignant melanoma.
  • BACKGROUND: In-transit metastases from cutaneous malignant melanoma (cutaneous or subcutaneous deposits between the primary melanoma and regional lymph nodes) represent late-stage disease, and their treatment should be tailored accordingly.
  • This article reviews the pathology, clinical significance and treatment options for in-transit disease from melanoma.
  • METHODS: An initial Medline search was undertaken using the keywords 'melanoma and in-transit' and 'melanoma and non-nodal regional recurrence'.
  • The method of treatment should be tailored to the extent of cutaneous disease.
  • The first line of treatment remains complete excision with negative histopathological margins.
  • Carbon dioxide laser therapy is valuable for multiple small cutaneous deposits.
  • Systemic chemotherapy has response rates of about 25 per cent and is reserved for patients for whom surgery is no longer feasible.
  • [MeSH-major] Melanoma / secondary. Melanoma / surgery. Skin Neoplasms / surgery
  • [MeSH-minor] Amputation. Chemotherapy, Cancer, Regional Perfusion. Humans. Laser Therapy / methods. Lymphatic Metastasis. Neoplasm Recurrence, Local / etiology. Risk Factors. Terminology as Topic

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2004 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.
  • (PMID = 15164434.001).
  • [ISSN] 0007-1323
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


14. Atallah E, Flaherty L: Treatment of metastatic malignant melanoma. Curr Treat Options Oncol; 2005 May;6(3):185-93
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of metastatic malignant melanoma.
  • The rapid increase in incidence of malignant melanoma has not been associated with better therapeutic options over the years.
  • Single-agent chemotherapy or immunotherapy remain the treatments of choice when systemic therapy is offered.
  • Dacarbazine (DTIC) is the chemotherapy of choice with a response rate of 16%.
  • However, in randomized phase III trials the two most active chemotherapy combination regimens, cisplatin, vinblastine, and DTIC (CVD) and the Dartmouth regimen (DTIC, cisplatin, bischloroethylnitrosourea , and tamoxifen), did not prove to be superior to single-agent DTIC for overall survival.
  • In patients who achieve a complete response, responses can be of greater durability than those with chemotherapy.
  • However, IL-2 and IFN administration are associated with multiple side effects, and only physicians experienced in the management of such therapies should administer them.
  • The potential benefit of combining chemotherapy with immunotherapy has led to multiple phase II trials of biochemotherapy that appeared to be associated with higher response rates and longer median survivals.
  • However, several phase III trials have been completed that have not consistently demonstrated an improvement in either response rates or overall survival, and these approaches to therapy cannot be routinely recommended outside the context of a clinical trial.
  • In our opinion, if complete metastasectomy is not feasible and in the absence of brain metastases, single-agent IL-2 is a good initial treatment choice in appropriately selected patients.
  • Single-agent chemotherapy with DTIC is the treatment of choice for patients who are not candidates for IL-2.
  • Adoptive immunotherapy combining nonmyeloablative chemotherapy with high-dose IL-2 is a potentially promising therapeutic strategy under investigation.
  • Targeted therapy is also an area of promising development as single agents, in combination, and combined with chemotherapy.
  • [MeSH-major] Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Immunotherapy. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):161-6 [15075910.001]
  • [Cites] Melanoma Res. 1995 Oct;5(5):365-9 [8541728.001]
  • [Cites] Cancer. 2000 Nov 1;89(9):1983-91 [11064356.001]
  • [Cites] Neurosurgery. 1999 Jan;44(1):59-64; discussion 64-6 [9894964.001]
  • [Cites] CA Cancer J Clin. 2004 Jan-Feb;54(1):8-29 [14974761.001]
  • [Cites] J Clin Oncol. 1999 Sep;17(9):2745-51 [10561349.001]
  • [Cites] J Surg Oncol. 2004 Oct 1;88(1):1-3 [15384062.001]
  • [Cites] J Clin Oncol. 1987 Apr;5(4):574-8 [3031224.001]
  • [Cites] J Clin Oncol. 2002 Apr 15;20(8):2045-52 [11956264.001]
  • [Cites] J Immunother. 2001 Jul-Aug;24(4):287-93 [11565830.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1743-51 [9586887.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2024-9 [2804890.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] J Clin Oncol. 2003 Sep 1;21(17 ):3351-6 [12947072.001]
  • [Cites] Melanoma Res. 2003 Dec;13(6):619-26 [14646626.001]
  • [Cites] Melanoma Res. 2004 Oct;14 (5):415-20 [15457099.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):193-201 [7670677.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):209-13 [10440757.001]
  • [Cites] Semin Surg Oncol. 1996 Nov-Dec;12(6):416-28 [8914206.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] Cancer Treat Rep. 1982 Jan;66(1):31-5 [6796269.001]
  • [Cites] J Clin Oncol. 2000 Jan;18(1):158-66 [10623706.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2345-53 [9191522.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Oct 5;101 Suppl 2:14639-45 [15381769.001]
  • [Cites] Semin Oncol. 2002 Oct;29(5):427-45 [12407508.001]
  • [Cites] Semin Oncol. 1997 Feb;24(1 Suppl 4):S24-31 [9122731.001]
  • [Cites] N Engl J Med. 2004 Sep 2;351(10 ):998-1012 [15342808.001]
  • (PMID = 15869730.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 31
  •  go-up   go-down


15. Essner R: Surgical treatment of malignant melanoma. Surg Clin North Am; 2003 Feb;83(1):109-56
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of malignant melanoma.
  • The surgical management of melanoma has evolved over the last 100 years. when early concepts of lymphatic permeation of the tumors and metastases led surgeons to perform radical operative procedures.
  • Wide excision of primary melanoma is now performed with 1- to 2-cm radial margins, significantly reducing the need for complex plastic closures, skin grafts. and hospital admissions.
  • Although elective lymph node dissection remains controversial as a therapeutic procedure, the development of SL has improved the staging of the regional lymph nodes and diminished the morbidity of lymph node dissection.
  • The role of SL for routine care of melanoma patients remains unknown.
  • Metastasectomy, which is the surgical resection of distant metastases with tumor-free surgical margins, has not been popular for AJCC stage IV patients with multiple metastases, because surgery is considered a local therapy and therefore of little value for management of disseminated disease.
  • Nevertheless, the many reports of long-term survival after resection of distant melanoma metastases to diverse soft tissue and organ sites clearly indicate that this form of cytoreductive surgery can be extremely successful in carefully selected patients.
  • Unlike chemotherapy, complete surgical metastasectomy can rapidly render a patient disease-free with only a short period of postoperative morbidity.
  • Most patients fully recover from the surgical procedure within 6 weeks, returning to most or all activities.
  • The ability to select patients for surgery is based on the development of more sophisticated imaging techniques, which allow better preoperative differentiation of patients with single versus multiple metastases and improve the surgeon's ability to identify and resect multiple metastatic sites.
  • We believe that increased understanding of the biology of the primary and metastases, dramatic improvement in the accuracy of staging metastatic disease, and better techniques of surgical resection provide the best chance for long-term palliation or cure of melanoma.
  • The long-term clinical benefit of this therapy depends on the patient's immune response to, the surgical reduction in tumor burden: an immune response that controls subclinical micrometastases should optimize postoperative survival.
  • [MeSH-major] Melanoma / surgery. Skin Neoplasms / surgery

  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12691453.001).
  • [ISSN] 0039-6109
  • [Journal-full-title] The Surgical clinics of North America
  • [ISO-abbreviation] Surg. Clin. North Am.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 267
  •  go-up   go-down


16. Sun W, Schuchter LM: Metastatic melanoma. Curr Treat Options Oncol; 2001 Jun;2(3):193-202
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic melanoma.
  • The overall survival for patients with metastatic melanoma ranges from 4.7 to 11 months, with a median survival of 8.5 months.
  • Standard treatment for patients with metastatic melanoma has not been defined.
  • The range of treatment options includes close observation, surgical resection of isolated metastases, therapy with dacarbazine, combination chemotherapy, and participation in clinical trials.
  • Numerous chemotherapeutic agents have shown activity in the treatment of malignant melanoma.
  • Dacarbazine (DTIC-Dome; Bayer Corporation, West Haven, CT) has a response rate of 15% to 20% and remains the reference agent for the treatment of metastatic disease.
  • Combination chemotherapy with or without tamoxifen has been extensively evaluated in patients with metastatic melanoma.
  • There has been widespread interest in developing immunotherapies against metastatic melanoma.
  • Biochemotherapy, which is a combination of immunotherapy and cytotoxic chemotherapy, has been studied in patients with metastatic melanoma.
  • Multiple phase II studies have demonstrated high response rates but unclear impact on overall survival.
  • Therapy is associated with significant toxicity.
  • Ongoing randomized clinical trials will clarify the role of biochemotherapy in patients with metastatic melanoma.
  • Ongoing new approaches to treatment include the therapeutic use of vaccines alone or in combination with cytokines.
  • [MeSH-major] Melanoma / therapy. Skin Neoplasms / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Clinical Trials as Topic. Combined Modality Therapy. Humans. Immunotherapy. Interferon-alpha / therapeutic use. Interleukin-2 / therapeutic use. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1991 Sep;9(9):1687-91 [1875225.001]
  • [Cites] J Clin Oncol. 1999 Mar;17 (3):968-75 [10071291.001]
  • [Cites] Int J Cancer. 1992 Feb 20;50(4):553-6 [1537621.001]
  • [Cites] Surgery. 1994 Mar;115(3):295-302 [8128354.001]
  • [Cites] Br Med Bull. 1995 Jul;51(3):609-30 [7552084.001]
  • [Cites] J Clin Oncol. 1992 Aug;10 (8):1338-43 [1634924.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1743-51 [9586887.001]
  • [Cites] Cancer. 1989 Nov 15;64(10):2024-9 [2804890.001]
  • [Cites] Cancer. 1990 Jun 1;65(11):2478-81 [1970948.001]
  • [Cites] J Clin Oncol. 1999 Jul;17(7):2105-16 [10561265.001]
  • [Cites] Cancer. 1984 Mar 15;53(6):1299-305 [6362841.001]
  • [Cites] Curr Opin Oncol. 1996 Mar;8(2):167-74 [8727310.001]
  • [Cites] Curr Opin Oncol. 1997 Mar;9(2):205-13 [9161801.001]
  • [Cites] Invest New Drugs. 1991 Feb;9(1):59-64 [1673965.001]
  • [Cites] J Am Coll Surg. 1995 Sep;181(3):193-201 [7670677.001]
  • [Cites] J Clin Oncol. 1993 Oct;11(10 ):1969-77 [8410122.001]
  • [Cites] J Clin Oncol. 1995 Apr;13(4):910-3 [7707118.001]
  • [Cites] J Clin Oncol. 1994 Aug;12(8):1553-60 [8040667.001]
  • [Cites] J Clin Oncol. 1996 Jan;14 (1):7-17 [8558223.001]
  • [Cites] Med Oncol. 1996 Jun;13(2):111-7 [9013474.001]
  • [Cites] Cancer. 1989 Jan 15;63(2):224-7 [2642731.001]
  • [Cites] J Clin Oncol. 1998 May;16(5):1752-9 [9586888.001]
  • [Cites] Cancer Treat Rep. 1984 Nov;68(11):1403-5 [6541973.001]
  • [Cites] J Clin Oncol. 1998 Feb;16(2):664-9 [9469356.001]
  • (PMID = 12057119.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Interferon-alpha; 0 / Interleukin-2
  • [Number-of-references] 27
  •  go-up   go-down


17. Rothfels H, Paschen A, Schadendorf D: Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma. Exp Dermatol; 2003 Dec;12(6):799-810
Hazardous Substances Data Bank. METHYLTHIAZOLETETRAZOLIUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Evaluation of combined gene regulatory elements for transcriptional targeting of suicide gene expression to malignant melanoma.
  • Selective killing of tumors can be achieved by targeting the transcription of suicide genes via specific DNA control elements to malignant cells.
  • Three different enhancer-promoter systems were constructed and evaluated for their capability to direct gene expression to melanoma.
  • Two tissue-specific (tyrosine and MIA) promoters and one weak viral promoter were fused to multiple tandem copies of a melanocyte-specific enhancer element.
  • Reporter gene assays revealed a maximum increase in transcription by combining each promoter with 3-4 copies of the enhancer and demonstrated that all enhancer-promoter combinations exhibited tissue-specific activity.
  • In contrast, when those combinations were employed to drive the expression of two suicide genes, encoding the diptheria toxin A chain (DT-A) and the prodrug-activating herpes simplex virus thymidine kinase (TK), respectively, only those constructs in which transcription was under control of tissue-specific promoter elements mediated selective killing of melanoma cells.
  • Our data indicate that the enhancer/tyrosinase and enhancer/MIA promoter constructs but not the viral promoter constructs can provide a valuable tool for selective suicide gene expression in melanoma.
  • [MeSH-major] Gene Expression Regulation, Neoplastic. Genes, Regulator. Genetic Therapy / methods. Melanoma / pathology. Transcription, Genetic
  • [MeSH-minor] Animals. Cell Death. Cell Line. Cell Line, Tumor. Chloramphenicol O-Acetyltransferase / genetics. Chloramphenicol O-Acetyltransferase / metabolism. Coloring Agents / pharmacology. Cytomegalovirus / genetics. DNA / genetics. Enhancer Elements, Genetic. Genes, Reporter. HeLa Cells. Humans. Mice. Neoplasm Metastasis. Plasmids / metabolism. Promoter Regions, Genetic. Tetrazolium Salts / pharmacology. Thiazoles / pharmacology. Time Factors. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14714561.001).
  • [ISSN] 0906-6705
  • [Journal-full-title] Experimental dermatology
  • [ISO-abbreviation] Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Coloring Agents; 0 / Tetrazolium Salts; 0 / Thiazoles; 298-93-1 / thiazolyl blue; 9007-49-2 / DNA; EC 2.3.1.28 / Chloramphenicol O-Acetyltransferase
  •  go-up   go-down


18. Bruno G, Coppola M, Eleuteri E, Barucco M, Molfetta R, Bruno A, Angelini L: An unusual association of malignant melanoma and small cell lung cancer: case report. An eleven-year-follow-up. Clin Ter; 2003 Jul-Aug;154(4):271-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual association of malignant melanoma and small cell lung cancer: case report. An eleven-year-follow-up.
  • The authors report the case of a patient affected by malignant melanoma and small cell lung cancer.
  • After having underlined the rareness of this pathological association, reviewing the most recent literature, the description of the clinical case aims at opening a discussion on how the surgical treatment performed, associated to chemotherapy, brought to an unhoped-for success, also helped by an unexpected combination of events that were absolutely out of any protocol.
  • [MeSH-major] Carcinoma, Small Cell. Lung Neoplasms. Melanoma. Skin Neoplasms
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Neoplasms, Multiple Primary / diagnosis. Neoplasms, Multiple Primary / surgery. Time Factors


19. Schwager SS, Leiter U, Buettner PG, Voit C, Marsch W, Gutzmer R, Näher H, Gollnick H, Bröcker EB, Garbe C: Management of primary and metastasized melanoma in Germany in the time period 1976-2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society. Melanoma Res; 2008 Apr;18(2):112-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Management of primary and metastasized melanoma in Germany in the time period 1976-2005: an analysis of the Central Malignant Melanoma Registry of the German Dermatological Society.
  • The study also evaluated surgical management in different geographical regions and treatment options for metastasized melanoma.
  • A total of 42 625 patients with invasive primary cutaneous melanoma, recorded by the German Central Malignant Melanoma Registry between 1976 and 2005 were included.
  • Multiple linear regression analysis was used to investigate time trends of excision margins adjusted for tumour thickness.
  • In the case of primary melanoma, one-step surgery dominated until 1985 and was mostly replaced by two-step excisions since the early 1990s.
  • During the last three decades loco-regional metastases were predominantly treated by surgery (up to 80%), whereas systemic therapy decreased.
  • The primary treatment of distant metastases has consistently been systemic chemotherapy.
  • A significant trend towards two-step excisions in primary cutaneous melanoma was observed throughout Germany.
  • Management of metastasized melanoma showed a tendency towards surgical procedures in limited disease and an ongoing trend to systemic treatment in advanced disease.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Melanoma / secondary. Melanoma / therapy. Skin Neoplasms / therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18337647.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


20. Reiriz AB, Richter MF, Fernandes S, Cancela AI, Costa TD, Di Leone LP, Schwartsmann G: Phase II study of thalidomide in patients with metastatic malignant melanoma. Melanoma Res; 2004 Dec;14(6):527-31
Hazardous Substances Data Bank. THALIDOMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II study of thalidomide in patients with metastatic malignant melanoma.
  • Thalidomide has anti-angiogenic and immunomodulatory activity, exhibiting antitumour effects in patients with multiple myeloma and, more rarely, in several other solid tumours.
  • We evaluated the single-agent antitumour activity and toxicity profile of thalidomide in patients with metastatic malignant melanoma, as well as its plasma pharmacokinetics and pharmacodynamic effects [vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (b-FGF) levels].
  • Other toxicities were oedema, neuropathy, dry skin, dry mouth, tremor and fatigue.
  • The plasma pharmacokinetics of thalidomide were comparable with those of previous studies in normal volunteers and in patients with advanced prostate cancer.
  • Serum levels of b-FGF and VEGF did not change significantly following drug administration.
  • In conclusion, thalidomide showed poor activity, but acceptable toxicity, in patients with metastatic melanoma.
  • [MeSH-major] Angiogenesis Inhibitors / therapeutic use. Melanoma / drug therapy. Neoplasm Recurrence, Local / drug therapy. Neovascularization, Pathologic / prevention & control. Skin Neoplasms / drug therapy. Thalidomide / therapeutic use
  • [MeSH-minor] Administration, Oral. Adult. Aged. Drug Administration Schedule. Female. Fibroblast Growth Factor 2 / metabolism. Humans. Maximum Tolerated Dose. Middle Aged. Survival Rate. Treatment Outcome. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15577325.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Vascular Endothelial Growth Factor A; 103107-01-3 / Fibroblast Growth Factor 2; 4Z8R6ORS6L / Thalidomide
  •  go-up   go-down


21. Bong AB, Bonnekoh B, Franke I, Schön M, Ulrich J, Gollnick H: Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma. Dermatology; 2002;205(2):135-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imiquimod, a topical immune response modifier, in the treatment of cutaneous metastases of malignant melanoma.
  • BACKGROUND: Imiquimod 5% cream (Aldara, a novel topical immune response modifier, has been approved for the topical treatment of anogenital HPV-induced warts.
  • AIM: Given the convincing therapeutic results of imiquimod when used for treating selected types of epithelial skin cancer, we became interested to study imiquimod as an adjuvant for treating cutaneous metastases of malignant melanoma.
  • METHODS: Three patients with multiple, i.e. more than 15, cutaneous in-transit metastases of malignant melanoma in unilateral localization on the leg were treated topically with imiquimod 5% cream.
  • CONCLUSION: Overall, imiquimod as a single agent or in combination with intralesional IL-2 may be a promising immunomodulatory compound for the adjuvant topical treatment of patients with multiple cutaneous metastases of malignant melanoma.
  • [MeSH-major] Adjuvants, Immunologic / administration & dosage. Aminoquinolines / administration & dosage. Antineoplastic Agents / administration & dosage. Melanoma / drug therapy. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. Imiquimod .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 S. Karger AG, Basel
  • (PMID = 12218228.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Aminoquinolines; 0 / Antineoplastic Agents; 0 / Interleukin-2; P1QW714R7M / imiquimod
  •  go-up   go-down


22. des Grottes JM, Dumon JC, Body JJ: Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates. Melanoma Res; 2001 Oct;11(5):477-82
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypercalcaemia of melanoma: incidence, pathogenesis and therapy with bisphosphonates.
  • Tumour-induced hypercalcaemia (TIH) is a frequent complication of advanced cancer but has been rarely reported in patients with malignant melanoma, and its pathogenesis remains unexplored.
  • We studied eight patients with TIH and melanoma.
  • We determined the incidence and pathogenesis of this complication and the effects of bisphosphonate therapy.
  • The incidence of TIH in 751 patients with melanoma was 1.1%.
  • All patients had liver and bone metastases at the time of hypercalcaemia.
  • All patients had osteolytic lesions, most often multiple.
  • Three of four patients became normocalcaemic after bisphosphonate therapy for a median duration of 2 weeks.
  • In conclusion, hypercalcaemia is a rare complication of melanoma.
  • [MeSH-major] Diphosphonates / therapeutic use. Hypercalcemia / complications. Hypercalcemia / drug therapy. Melanoma / complications. Skin Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Bone Neoplasms / metabolism. Bone Neoplasms / pathology. Bone Neoplasms / secondary. Bone Resorption. Calcium / blood. Calcium / metabolism. Calcium / urine. Female. Humans. Incidence. Kidney / metabolism. Liver Neoplasms / metabolism. Liver Neoplasms / pathology. Liver Neoplasms / secretion. Lumbar Vertebrae / metabolism. Lumbar Vertebrae / pathology. Male. Middle Aged. Osteogenesis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CALCIUM, ELEMENTAL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11595884.001).
  • [ISSN] 0960-8931
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Diphosphonates; SY7Q814VUP / Calcium
  •  go-up   go-down


23. Tas F, Kurul S, Camlica H, Topuz E: Malignant melanoma in Turkey: a single institution's experience on 475 cases. Jpn J Clin Oncol; 2006 Dec;36(12):794-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant melanoma in Turkey: a single institution's experience on 475 cases.
  • BACKGROUND: This study was performed to determine the characteristics and the clinical outcomes of patients with cutaneous melanoma in Turkey.
  • METHODS: The medical records of patients between 1991 and 2003 at Institute of Oncology were retrieved from the cancer registry.
  • RESULTS: Of the 475 adult cases with complete staging procedure, the incidence of localized (stages I-II) disease was 301 (63.4%), and followed by node involved (stage III) and metastatic (stage IV) disease with the incidence of 117 (24.6%) and 57 (12.0%), respectively.
  • The superficial spreading type was the commonest histology (52.2%).
  • Unresponsiveness to chemotherapy, visceral metastasis, multiple metastases and not given chemotherapy were the poor prognostic factors for overall survival.
  • [MeSH-major] Melanoma / epidemiology. Skin Neoplasms / epidemiology

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17060409.001).
  • [ISSN] 0368-2811
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


24. Schrofer C, Villiger P, Cathomas R: [Multiple primary neoplasms - coincidence or tumor syndrom?]. Praxis (Bern 1994); 2009 Sep 9;98(18):1027-31
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multiple primary neoplasms - coincidence or tumor syndrom?].
  • BACKGROUND: Multiple primary neoplasms occur either by hazard or in the context of hereditary cancer syndromes, after chronic toxic exposition, in immunodeficiency or as secondary malignancies after radio- and/or chemotherapy.
  • CASE REPORT: We present the history of an actually asymptomatic female patient with four different malignancies within 30 years: malignant melanoma (1976), liposarcoma (1983), carcinoma of the appendix (2006) and lymphoma (2006).
  • DISCUSSION: There is not only a remarkable variety of malignant tumors but also an extraordinary long survival without recurrence of the generalised malignomas of the skin and soft tissue (malignant melanoma and liposarcoma).
  • It is difficult to explain the entire restitution with the implemented treatments (several tumor resections, chemotherapy with Ifosfamide).
  • More than 20 years after chemotherapy, the lymphoma can be classified as a secondary malignoma.
  • We discuss the pathogenesis of multiple malignomas in further details.
  • [MeSH-major] Adenocarcinoma, Mucinous / diagnosis. Appendiceal Neoplasms / diagnosis. Ileal Neoplasms / diagnosis. Liposarcoma / diagnosis. Lymphoma, Follicular / diagnosis. Melanoma / diagnosis. Neoplasms, Second Primary / diagnosis. Skin Neoplasms / diagnosis. Soft Tissue Neoplasms / diagnosis
  • [MeSH-minor] Aged. Combined Modality Therapy. Female. Humans. Lymph Nodes / pathology. Neoplasm Staging. Syndrome

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19739050.001).
  • [ISSN] 1661-8157
  • [Journal-full-title] Praxis
  • [ISO-abbreviation] Praxis (Bern 1994)
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Eberle J, Kurbanov BM, Hossini AM, Trefzer U, Fecker LF: Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches. Drug Resist Updat; 2007 Dec;10(6):218-34
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Overcoming apoptosis deficiency of melanoma-hope for new therapeutic approaches.
  • The increased incidence of malignant melanoma in the last decades, its high mortality and pronounced therapy resistance pose an enormous challenge.
  • Important therapeutic targets for melanoma are the induction of apoptosis and suppression of survival pathways.
  • Preclinical studies have demonstrated the efficacy of pro-apoptotic Bcl-2 proteins and of death receptor ligands to trigger apoptosis in melanoma cells.
  • In the clinical setting, BH3 domain mimics and death receptor agonists are therefore considered as promising, specific novel treatments to add to the conventional pro-apoptotic strategies such as chemo- or radiotherapy.
  • However, constitutively activated survival pathways, in particular the mitogen-activated protein kinases, protein kinase B/Akt and nuclear factor (NF)-kappaB, all may work in concert to prevent effective therapy.
  • Thus, selective biologicals developed with the aim to inhibit pro-survival signaling are currently tested in melanoma.
  • For highly therapy-resistant tumors such as melanoma, development of novel drug combinations will be essential, and combinations of survival inhibitors and pro-apoptotic mediators appear most promising.
  • The challenge of the near future will be to make a rational choice of the multiple possible combinations and protocols.
  • This review gives a critical overview of proteins involved in melanoma chemoresistance, which are targets for current drug development leading to the best choice for future trials.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Apoptosis / drug effects. Melanoma / drug therapy. Signal Transduction / drug effects
  • [MeSH-minor] Animals. Caspases / metabolism. Cell Survival / drug effects. Cysteine Proteinase Inhibitors / therapeutic use. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Humans. Intracellular Signaling Peptides and Proteins / metabolism. Mutation. Protein Kinase Inhibitors / therapeutic use. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Proto-Oncogene Proteins c-bcl-2 / metabolism. Receptors, Death Domain / agonists. Receptors, Death Domain / metabolism. Tumor Suppressor Protein p53 / metabolism

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Melanoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18054518.001).
  • [ISSN] 1532-2084
  • [Journal-full-title] Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy
  • [ISO-abbreviation] Drug Resist. Updat.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Scotland
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Cysteine Proteinase Inhibitors; 0 / Intracellular Signaling Peptides and Proteins; 0 / Protein Kinase Inhibitors; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Receptors, Death Domain; 0 / Tumor Suppressor Protein p53; EC 3.4.22.- / Caspases
  • [Number-of-references] 215
  •  go-up   go-down


26. Sorolla A, Yeramian A, Dolcet X, Pérez de Santos AM, Llobet D, Schoenenberger JA, Casanova JM, Soria X, Egido R, Llombart A, Vilella R, Matias-Guiu X, Marti RM: Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines. Br J Dermatol; 2008 Mar;158(3):496-504
Hazardous Substances Data Bank. BORTEZOMIB .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of proteasome inhibitors on proliferation and apoptosis of human cutaneous melanoma-derived cell lines.
  • BACKGROUND: Cutaneous malignant melanoma is an aggressive type of skin cancer which causes disproportionate mortality in young and middle-aged adults.
  • Once disseminated, melanoma can be considered an incurable disease, highly resistant to standard antineoplastic treatment, such as chemotherapy or radiation therapy.
  • The proteasome represents a novel target for cancer therapy that can potentially be used in melanoma.
  • OBJECTIVES: To assess the effect of four structurally different proteasome inhibitors on human cutaneous melanoma-derived cell lines.
  • METHODS: Sixteen human cutaneous melanoma-derived cell lines which are original were obtained from patients who were treated by two of the authors.
  • RESULTS: Proteasome inhibitors inhibited the in vitro growth of melanoma cells, and this effect was due to a reduction in cell proliferation rate and an induction of both caspase-dependent and caspase-independent cell death.
  • CONCLUSIONS: This study provides information regarding the in vitro effects of proteasome inhibitors on melanoma cell lines, and the molecular mechanisms involved.
  • It also gives support to the future use of such inhibitors in the treatment of patients with melanoma, either administered alone or in combination with other drugs.
  • [MeSH-major] Apoptosis / drug effects. Boronic Acids / pharmacology. Cell Death / drug effects. Melanoma / drug therapy. Protease Inhibitors / pharmacology. Pyrazines / pharmacology. Skin Neoplasms / drug therapy
  • [MeSH-minor] Bortezomib. Cell Line, Tumor. Cell Proliferation / drug effects. Drug Resistance, Multiple. Female. Humans. Male. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18205878.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Boronic Acids; 0 / Protease Inhibitors; 0 / Pyrazines; 69G8BD63PP / Bortezomib
  •  go-up   go-down


27. Kovach BT, Sams HH, Stasko T: Systemic strategies for chemoprevention of skin cancers in transplant recipients. Clin Transplant; 2005 Dec;19(6):726-34
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Systemic strategies for chemoprevention of skin cancers in transplant recipients.
  • Management of malignant and pre-malignant cutaneous lesions in transplant recipients is challenging, making prevention of such neoplasms paramount.
  • The objectives of the present study are to review and analyze systemic strategies for chemoprevention of malignant and pre-malignant cutaneous neoplasms in OTRs.
  • METHODS: MEDLINE and PubMed searches were performed to identify studies with original data quantifying the effects of systemic agents on the development of malignant cutaneous neoplasms in patients with solid organ transplants.
  • A majority of the studies found a decrease in the number of malignant and pre-malignant cutaneous lesions in patients treated with systemic retinoids, with several studies noting increased benefit in those patients with multiple previous skin cancers.
  • Multiple studies described a rebound effect, with increased numbers of neoplasms occurring following discontinuation of retinoids.
  • No studies were identified that adequately quantified the effects of other systemic agents on skin cancer incidence in this population.
  • Although optimal dosing and indications for initiation of systemic retinoid therapy are not conclusive from the data, it suggests that retinoids are most effective in patients with multiple previous non-melanoma skin cancers.
  • Further investigation through randomized controlled trials is needed to further clarify the tolerability and efficacy of multiple dosing regimens on the incidence of pre-malignant and malignant lesions in transplant recipients.
  • The therapeutic role of other systemic agents in the transplant population has not been established.
  • [MeSH-major] Carcinoma, Squamous Cell / prevention & control. Organ Transplantation / adverse effects. Precancerous Conditions / drug therapy. Retinoids / therapeutic use. Skin Neoplasms / prevention & control
  • [MeSH-minor] Cyclooxygenase 2 Inhibitors / therapeutic use. Humans

  • MedlinePlus Health Information. consumer health - Organ Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16313317.001).
  • [ISSN] 0902-0063
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Cyclooxygenase 2 Inhibitors; 0 / Retinoids
  • [Number-of-references] 53
  •  go-up   go-down


28. Thamm DH, Huelsmeyer MK, Mitzey AM, Qurollo B, Rose BJ, Kurzman ID: RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target. Melanoma Res; 2010 Feb;20(1):35-42
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RT-PCR-based tyrosine kinase display profiling of canine melanoma: IGF-1 receptor as a potential therapeutic target.
  • Canine malignant melanoma (CMM) resembles human malignant melanoma in terms of metastatic behavior, refractoriness to standard therapy, and tumor antigen expression but it is largely unknown how CMM resembles human melanoma with regard to molecular pathogenesis and cellular signaling.
  • This study used a reverse transcription-PCR display technique to evaluate the expression of multiple TKs in the 17CM98 CMM cell line.
  • Interestingly, IGF-1R, JAK1, and Axl were detected in human melanoma using similar techniques, supporting the cross-species validity of this assay.
  • Expression of IGF-1R mRNA was detected in five of five additional CMM cell cultures, and IGF-1R protein was detected in five of six primary tumors evaluated, suggesting that IGF-1R expression may be common in CMM and may provide a novel target for future therapy.
  • In conclusion, this study suggests that similar TKs are expressed in human and canine melanoma, and shows potential antitumor effects of IGF-1R inhibition in CMM.
  • [MeSH-major] Dog Diseases / enzymology. Melanoma / enzymology. Melanoma / veterinary. Protein-Tyrosine Kinases / biosynthesis. Receptor, IGF Type 1 / antagonists & inhibitors. Reverse Transcriptase Polymerase Chain Reaction / veterinary. Skin Neoplasms / veterinary
  • [MeSH-minor] Animals. Cell Line, Tumor. Dogs. Humans. Protein Kinase Inhibitors / pharmacology. Pyrimidines / pharmacology. Pyrroles / pharmacology. Signal Transduction / drug effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19949352.001).
  • [ISSN] 1473-5636
  • [Journal-full-title] Melanoma research
  • [ISO-abbreviation] Melanoma Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / ADW 742; 0 / Protein Kinase Inhibitors; 0 / Pyrimidines; 0 / Pyrroles; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor, IGF Type 1
  •  go-up   go-down


29. Cienki JJ, Zaret L: An Internet misadventure: bloodroot salve toxicity. J Altern Complement Med; 2010 Oct;16(10):1125-7
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Herbalists prescribe bloodroot for multiple conditions including skin lesions and sore throats.
  • We report 2 patients who treated skin lesions with bloodroot to untoward effect.
  • CASE REPORT 1: A 53-year-old man with unremarkable medical history developed a 5-mm papule on his chest that gradually blackened.
  • The patient searched the Internet for "herbal cures" and found bloodroot salve as a therapy for skin lesions.
  • The patient restarted bloodroot treatments despite intense pain.
  • Pathological examination of the lesion revealed malignant melanoma.
  • CASE REPORT 2: A 42-year-old man with a history of metastatic colon cancer developed palpable subcutaneous nodules on the anterior abdominal wall.
  • The patient's mother searched the Internet for cancer salves and purchased black and yellow bloodroot salve.
  • Web sites discuss the efficacy of bloodroot in treating skin cancer.
  • The cases describe attempts to self-treat skin lesions with unregulated Internet therapy.
  • Lack of regulation of information on the Internet allows alternative therapies to be promoted without full consideration of potential toxicity.
  • [MeSH-major] Colonic Neoplasms / drug therapy. Internet. Plant Extracts / toxicity. Sanguinaria / toxicity. Self Medication. Skin Diseases / drug therapy
  • [MeSH-minor] Abdomen / pathology. Adult. Humans. Intestinal Fistula. Male. Melanoma. Middle Aged. Pain / etiology. Phytotherapy / adverse effects. Thorax / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20932193.001).
  • [ISSN] 1557-7708
  • [Journal-full-title] Journal of alternative and complementary medicine (New York, N.Y.)
  • [ISO-abbreviation] J Altern Complement Med
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Plant Extracts
  •  go-up   go-down


30. Taylor CW, Dorr RT, Fanta P, Hersh EM, Salmon SE: A phase I and pharmacodynamic evaluation of polyethylene glycol-conjugated L-asparaginase in patients with advanced solid tumors. Cancer Chemother Pharmacol; 2001;47(1):83-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PEG-L-asparaginase was administered by intramuscular injection every 2 weeks to 28 patients with various types of advanced solid tumor malignancies.
  • RESULTS: The in vitro HTCA studies suggested good antitumor activity against malignant melanoma and multiple myeloma.
  • Three patients developed hypersensitivity reactions, but these were not dose related.
  • Two patients developed deep vein thromboses.
  • We saw no partial or complete responses in patients treated in this study, including 11 patients with malignant melanoma.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Asparaginase / therapeutic use. Glutaminase / therapeutic use. Neoplasms / drug therapy. Polyethylene Glycols / therapeutic use
  • [MeSH-minor] Adult. Asparagine / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Drug Screening Assays, Antitumor. Humans. Lung Neoplasms / drug therapy. Melanoma / drug therapy. Neoplasm Proteins / blood. Skin Neoplasms / drug therapy

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. ASPARAGINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11221967.001).
  • [ISSN] 0344-5704
  • [Journal-full-title] Cancer chemotherapy and pharmacology
  • [ISO-abbreviation] Cancer Chemother. Pharmacol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase I; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Neoplasm Proteins; 30IQX730WE / Polyethylene Glycols; 39335-03-0 / polyethylene glycol-glutaminase-asparaginase; 7006-34-0 / Asparagine; EC 3.5.1.1 / Asparaginase; EC 3.5.1.2 / Glutaminase
  •  go-up   go-down


31. Elhassadi E, Egan E, O'sullivan G, Mohamed R: Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma. Clin Lab Haematol; 2006 Aug;28(4):279-81
Hazardous Substances Data Bank. MELPHALAN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated limb infusion with cytotoxic agent for treatment of localized refractory cutaneous T-cell lymphoma.
  • We described a 57-yr-old male diagnosed with cutaneous T-cell lymphoma that had failed multiple treatment options, as his disease was mainly confined to one limb.
  • We attempted a novel approach in this condition using a technique of intra-arterial limb infusion with cytotoxic agent Melphalan (ILI) which has been proven beneficial in management of localised malignant melanoma.
  • This treatment approach was well tolerated with mild myelosuppression and moderate limb toxicity.
  • [MeSH-major] Antineoplastic Agents, Alkylating / administration & dosage. Chemotherapy, Cancer, Regional Perfusion / methods. Lymphoma, T-Cell, Cutaneous / drug therapy. Melphalan / administration & dosage. Skin Neoplasms / drug therapy

  • Genetic Alliance. consumer health - Cutaneous T-Cell Lymphoma.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16898971.001).
  • [ISSN] 0141-9854
  • [Journal-full-title] Clinical and laboratory haematology
  • [ISO-abbreviation] Clin Lab Haematol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Alkylating; Q41OR9510P / Melphalan
  •  go-up   go-down


32. Laffitte E, Revuz J: Thalidomide: an old drug with new clinical applications. Expert Opin Drug Saf; 2004 Jan;3(1):47-56
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thalidomide: an old drug with new clinical applications.
  • Thalidomide has been used in several cutaneous inflammatory disorders (e.g., erythema nodosum leprosum in lepromatous leprosy, cutaneous lupus erythematosus and severe aphtosis), cancers (e.g., relapsed/refractory multiple myeloma, malignant melanoma and systemic signs in cancer) and inflammatory conditions (e.g., Crohn's disease and rheumatoid arthritis).
  • Somnolence and rash are frequently reported when thalidomide is used at higher doses as an anticarcinogenic agent and can lead to dose reduction or treatment discontinuation depending on severity.
  • [MeSH-major] Adjuvants, Immunologic / therapeutic use. Angiogenesis Inhibitors / therapeutic use. Hypnotics and Sedatives / therapeutic use. Thalidomide / therapeutic use
  • [MeSH-minor] Clinical Trials as Topic. Humans. Inflammation / drug therapy. Neoplasms / blood supply. Neoplasms / drug therapy. Practice Guidelines as Topic. Skin Diseases / drug therapy. Tumor Necrosis Factor-alpha / biosynthesis

  • Hazardous Substances Data Bank. THALIDOMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14680461.001).
  • [ISSN] 1474-0338
  • [Journal-full-title] Expert opinion on drug safety
  • [ISO-abbreviation] Expert Opin Drug Saf
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Adjuvants, Immunologic; 0 / Angiogenesis Inhibitors; 0 / Hypnotics and Sedatives; 0 / Tumor Necrosis Factor-alpha; 4Z8R6ORS6L / Thalidomide
  • [Number-of-references] 111
  •  go-up   go-down


33. Basarab T, Millard TP, McGregor JM, Barker JN: Atypical pigmented lesions following extensive PUVA therapy. Clin Exp Dermatol; 2000 Mar;25(2):135-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Atypical pigmented lesions following extensive PUVA therapy.
  • We report a 38-year-old woman with psoriasis who developed multiple atypical lentigines following psoralen photochemotherapy (PUVA).
  • The lentigines first appeared 12 years ago, 3 years after she commenced intermittent PUVA treatment.
  • At present, a link between malignant melanoma and PUVA lentigines has not been established.
  • Instead, limited evidence suggests that PUVA lentigines may be more closely linked with the risk of nonmelanoma skin cancer.
  • [MeSH-major] Lentigo / etiology. PUVA Therapy / adverse effects
  • [MeSH-minor] Adult. Female. Humans. Psoriasis / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Clin Exp Dermatol. 2001 Jul;26(5):459 [11488842.001]
  • (PMID = 10733639.001).
  • [ISSN] 0307-6938
  • [Journal-full-title] Clinical and experimental dermatology
  • [ISO-abbreviation] Clin. Exp. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] ENGLAND
  •  go-up   go-down


34. Soffietti R, Rudā R, Mutani R: Management of brain metastases. J Neurol; 2002 Oct;249(10):1357-69
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Brain metastases occur in 20-40% of patients with cancer and their frequency has increased over time.
  • Lung, breast and skin (melanoma) are the commonest sources of brain metastases, and in up to 15% of patients the primary site remains unknown.
  • After the introduction of MRI, multiple lesions have outnumbered single lesions.
  • There are no pathognomonic features on CT or MRI that distinguish brain metastases from primary malignant brain tumors or nonneoplastic conditions: therefore a tissue diagnosis by biopsy should be always obtained in patients with unknown primary tumor before undergoing radiotherapy and/or chemotherapy.
  • Symptomatic therapy includes corticosteroids to reduce vasogenic cerebral edema and anticonvulsants to control seizures.
  • The combination of surgery and whole-brain radiotherapy (WBRT) is superior to WBRT alone for the treatment of single brain metastasis in patients with limited or absent systemic disease and good neurological condition.
  • WBRT alone is the treatment of choice in patients with single brain metastasis not amenable to surgery or radiosurgery, and with an active systemic disease, and in patients with multiple brain metastases.
  • The response rate of brain metastases to chemotherapy is similar to the response rate of the primary tumor and extracranial metastases, some tumor types being more chemosensitive (small cell lung carcinoma, breast carcinoma, germ cell tumors).
  • New radiosensitizers and cytotoxic or cytostatic agents, and innovative technique of drug delivery are being investigated.
  • [MeSH-major] Brain Neoplasms / diagnosis. Brain Neoplasms / secondary. Brain Neoplasms / therapy
  • [MeSH-minor] Adrenal Cortex Hormones / therapeutic use. Anticonvulsants / therapeutic use. Drug Therapy. Humans. Neurosurgery. Prognosis. Radiosurgery. Radiotherapy. Thromboembolism / therapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12382150.001).
  • [ISSN] 0340-5354
  • [Journal-full-title] Journal of neurology
  • [ISO-abbreviation] J. Neurol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticonvulsants
  • [Number-of-references] 134
  •  go-up   go-down


35. Leonardi CL, Toth D, Cather JC, Langley RG, Werther W, Compton P, Kwon P, Wetherill G, Curtin F, Menter A: A review of malignancies observed during efalizumab (Raptiva) clinical trials for plaque psoriasis. Dermatology; 2006;213(3):204-14
MedlinePlus Health Information. consumer health - Psoriasis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most therapies used for moderate to severe psoriasis are immunosuppressive.
  • Agents that depress immune function, including traditional psoriasis therapies, have been associated with an increased incidence of malignancies.
  • METHODS: Patient data were pooled from multiple phase III placebo-controlled, open-label efalizumab clinical trials, and the incidence rate of reported malignancies was calculated as a function of patient years of observation.
  • RESULTS: The efalizumab- and placebo-treated patients had similar incidence rates of malignancy, including lymphoproliferative disease, solid tumor, malignant melanoma and nonmelanoma skin cancer.
  • The incidence of nonmelanoma skin cancers, including basal cell carcinoma and squamous cell carcinoma, in patients receiving efalizumab or placebo was elevated relative to the external databases.
  • CONCLUSIONS: These results suggest that efalizumab treatment does not increase a patient's risk for malignancy.
  • The difference observed with nonmelanoma skin cancer may be due to biases introduced by the clinical trial methodology.
  • Additional patient observation is necessary to ascertain whether a link exists between efalizumab therapy and nonmelanoma skin cancer above that normally observed in psoriasis patients.
  • [MeSH-major] Antibodies, Monoclonal / adverse effects. Neoplasms / chemically induced. Psoriasis / drug therapy

  • Genetic Alliance. consumer health - Psoriasis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17033169.001).
  • [ISSN] 1018-8665
  • [Journal-full-title] Dermatology (Basel, Switzerland)
  • [ISO-abbreviation] Dermatology (Basel)
  • [Language] eng
  • [Publication-type] Comparative Study; Meta-Analysis
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / efalizumab
  •  go-up   go-down






Advertisement